The following table details the insider trading activities
(stock purchases, stock sales, and stock option exercises) of Usman Nassim since 2015.
This trader's CIK number is 1206872.
At the time of last reporting, Usman Nassim was the Officer of Gyre Therapeutics, Inc.. (stock ticker symbol GYRE).
Also see all insider trading activities at Gyre Therapeutics, Inc..
Insider Buying | Insider Sales | Option Exercises | |||||
---|---|---|---|---|---|---|---|
Year | Symbol | Shares | Value | Shares | Value | Shares | Value |
2024 | GYRE | 0 | $0 | 43,452 | $660,377 | 43,452 | $301,122 |
2022 | GYRE | 6,500 | $3,022 | 0 | $0 | 0 | $0 |
2021 | GYRE | 1,449 | $5,937 | 0 | $0 | 5,000 | $23,150 |
2020 | GYRE | 4,582 | $18,447 | 0 | $0 | 0 | $0 |
2019 | GYRE | 0 | $0 | 0 | $0 | 4,400 | $20,372 |
2018 | GYRE | 0 | $0 | 0 | $0 | 88 | $407 |
2015 | GYRE | 4,000 | $8,000 | 0 | $0 | 0 | $0 |
Trade Date | Symbol | Trade Type | Shares | Price ($) | Value ($) |
---|---|---|---|---|---|
2024-06-28 | GYRE | Option Ex | 3,452 | 6.93 | 23,922 |
2024-06-28 | GYRE | Sale | 3,452 | 12.00 | 41,437 |
2024-05-01 | GYRE | Option Ex | 20,000 | 6.93 | 138,600 |
2024-05-01 | GYRE | Sale | 20,000 | 14.80 | 295,940 |
2024-04-01 | GYRE | Option Ex | 20,000 | 6.93 | 138,600 |
2024-04-01 | GYRE | Sale | 20,000 | 16.15 | 323,000 |
2022-08-09 | CBIO | Buy | 3,250 | .47 | 1,527 |
2022-02-09 | CBIO | Buy | 3,250 | .46 | 1,495 |
2021-08-09 | CBIO | Buy | 867 | 3.62 | 3,138 |
2021-04-05 | CBIO | Option Ex | 5,000 | 4.63 | 23,150 |
2021-02-09 | CBIO | Buy | 582 | 4.81 | 2,799 |
2020-08-10 | CBIO | Buy | 582 | 4.81 | 2,799 |
2020-03-13 | CBIO | Buy | 4,000 | 3.91 | 15,648 |
2019-05-21 | CBIO | Option Ex | 4,400 | 4.63 | 20,372 |
2018-04-04 | CBIO | Option Ex | 88 | 4.63 | 407 |
2015-12-17 | CBIO | Buy | 4,000 | 2.00 | 8,000 |
Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Usman Nassim (Officer of Gyre Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.